OBJECTIVE: Adipokines are fat-derived hormones and cytokines with immune-modulating and metabolic properties. Most of them are associated with insulin resistance. The aim of the present investigation was to evaluate circulating levels of adipokines and glucose homeostasis in patients with inflammatory bowel disease (IBD) and to evaluate possible associations with the course and characteristics of the disease. METHODS: Serum leptin, resistin, visfatin, retinol-binding protein-4, adiponectin, glucose, insulin, and inflammatory parameters were analyzed in 93 patients with inactive IBD (49 with Crohn's disease [CD], 44 with ulcerative colitis [UC]), 35 patients with active IBD (18 with CD, 17 with UC), and 37 age- and body mass index-matched healthy controls. Ninety-two patients were followed for 6 mo. RESULTS: Leptin was similar in patients with IBD and controls, whereas resistin and visfatin were increased in patients with active disease but not in those in remission. In active and inactive disease, adiponectin was decreased (P < 0.001) and retinol-binding protein-4 was increased (P < 0.001) compared with controls. About 60% of patients with IBD showed increased levels of insulin, whereas serum glucose remained normal, resulting in increased homeostasis model assessment values in most patients. Hyperinsulinemia was associated with the decrease in adiponectin (r = -0.572, P < 0.001) and proved to be an independent protective factor for 6-mo maintenance of remission (P = 0.016). CONCLUSION: IBD led to largely similar alterations in circulating adipokines and hyperinsulinemia in patients with CD and those with UC. The unexpected protective effect of hyperinsulinemia on relapse rate denotes the role of the metabolic-inflammatory response as a modulator in IBD.
OBJECTIVE: Adipokines are fat-derived hormones and cytokines with immune-modulating and metabolic properties. Most of them are associated with insulin resistance. The aim of the present investigation was to evaluate circulating levels of adipokines and glucose homeostasis in patients with inflammatory bowel disease (IBD) and to evaluate possible associations with the course and characteristics of the disease. METHODS: Serum leptin, resistin, visfatin, retinol-binding protein-4, adiponectin, glucose, insulin, and inflammatory parameters were analyzed in 93 patients with inactive IBD (49 with Crohn's disease [CD], 44 with ulcerative colitis [UC]), 35 patients with active IBD (18 with CD, 17 with UC), and 37 age- and body mass index-matched healthy controls. Ninety-two patients were followed for 6 mo. RESULTS: Leptin was similar in patients with IBD and controls, whereas resistin and visfatin were increased in patients with active disease but not in those in remission. In active and inactive disease, adiponectin was decreased (P < 0.001) and retinol-binding protein-4 was increased (P < 0.001) compared with controls. About 60% of patients with IBD showed increased levels of insulin, whereas serum glucose remained normal, resulting in increased homeostasis model assessment values in most patients. Hyperinsulinemia was associated with the decrease in adiponectin (r = -0.572, P < 0.001) and proved to be an independent protective factor for 6-mo maintenance of remission (P = 0.016). CONCLUSION: IBD led to largely similar alterations in circulating adipokines and hyperinsulinemia in patients with CD and those with UC. The unexpected protective effect of hyperinsulinemia on relapse rate denotes the role of the metabolic-inflammatory response as a modulator in IBD.
Authors: Marek Waluga; Marek Hartleb; Grzegorz Boryczka; Michał Kukla; Krystyna Zwirska-Korczala Journal: World J Gastroenterol Date: 2014-06-14 Impact factor: 5.742
Authors: Farnaz Keyhani-Nejad; Martin Irmler; Frank Isken; Eva K Wirth; Johannes Beckers; Andreas L Birkenfeld; Andreas F H Pfeiffer Journal: Diabetologia Date: 2014-10-28 Impact factor: 10.122
Authors: Xiaochao Wei; Zhen Yang; Federico E Rey; Vanessa K Ridaura; Nicholas O Davidson; Jeffrey I Gordon; Clay F Semenkovich Journal: Cell Host Microbe Date: 2012-02-16 Impact factor: 21.023
Authors: Hayder H Al-Azzawi; Kathryn M Ziegler; Deborah A Swartz-Basile; Sue Wang; Henry A Pitt; Nicholas J Zyromski Journal: J Gastrointest Surg Date: 2011-06-10 Impact factor: 3.452
Authors: Scott V Harding; Olasunkanmi A J Adegoke; Keely G Fraser; Errol B Marliss; Stéphanie Chevalier; Scot R Kimball; Leonard S Jefferson; Linda J Wykes Journal: Pediatr Res Date: 2010-03 Impact factor: 3.756
Authors: Martin H Holtmann; Frank Krummenauer; Christina Claas; Kristina Kremeyer; Dirk Lorenz; Olivia Rainer; Iris Vogel; Ulrich Böcker; Stephan Böhm; Carsten Büning; Rainer Duchmann; Guido Gerken; Hans Herfarth; Norbert Lügering; Wolfgang Kruis; Max Reinshagen; Jan Schmidt; Andreas Stallmach; Jürgen Stein; Andreas Sturm; Peter R Galle; Daan W Hommes; Geert D'Haens; Paul Rutgeerts; Markus F Neurath Journal: Dig Dis Sci Date: 2009-06-10 Impact factor: 3.199
Authors: Shali Mazaki-Tovi; Roberto Romero; Edi Vaisbuch; Tinnakorn Chaiworapongsa; Offer Erez; Pooja Mittal; Sun Kwon Kim; Francesca Gotsch; Ronald Lamont; Giovanna Ogge; Percy Pacora; Luis Goncalves; Chong Jai Kim; Ricardo Gomez; Jimmy Espinoza; Sonia S Hassan; Juan Pedro Kusanovic Journal: J Perinat Med Date: 2010 Impact factor: 1.901